KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EBT (2017 - 2025)

Moderna (MRNA) has disclosed EBT for 9 consecutive years, with -$799.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 32.52% to -$799.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.8 billion, a 23.26% increase, with the full-year FY2025 number at -$2.8 billion, up 23.26% from a year prior.
  • EBT was -$799.0 million for Q4 2025 at Moderna, down from -$187.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $5.4 billion in Q4 2021 to a low of -$2.0 billion in Q3 2023.
  • A 5-year average of $627.2 million and a median of -$83.0 million in 2024 define the central range for EBT.
  • Peak YoY movement for EBT: soared 2727.72% in 2021, then plummeted 1791.43% in 2024.
  • Moderna's EBT stood at $5.4 billion in 2021, then tumbled by 69.41% to $1.7 billion in 2022, then tumbled by 95.77% to $70.0 million in 2023, then tumbled by 1791.43% to -$1.2 billion in 2024, then skyrocketed by 32.52% to -$799.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's EBT are -$799.0 million (Q4 2025), -$187.0 million (Q3 2025), and -$818.0 million (Q2 2025).